BC
AKBA icon

Birchview Capital’s Akebia Therapeutics AKBA Stock Holding History

Birchview Capital’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-20,000
Closed -$8.39K – 61
2022
Q1 		$14K Sell
20,000
-80,000
-80% -$171K 0.01% 63
2021
Q4 		$226K Hold
100,000
– – 0.15% 60
2021
Q3 		$288K Hold
100,000
– – 0.2% 53
2021
Q2 		$379K Buy
+100,000
New +$337K 0.23% 50

Other funds holding AKBA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Birchview Capital's AKBA Position: Q2 2022 in Review

Birchview Capital sold out of Akebia Therapeutics (AKBA) in Q2 2022, closing a stake of 20,000 shares — an estimated $8.39K sold.

Birchview Capital first reported a position in AKBA in Q2 2021 and held it in 4 quarters. The position peaked at $379K in Q2 2021. 96 funds tracked by Wall St. Rank hold AKBA as of Q2 2022.

  • Birchview Capital reported no remaining Akebia Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Birchview Capital sold 20,000 Akebia Therapeutics shares in Q2 2022, an estimated $8.39K.
  • Birchview Capital first reported a position in Akebia Therapeutics in Q2 2021 and held it in 4 quarters.
  • Birchview Capital's Akebia Therapeutics position peaked at $379K in Q2 2021.
  • 96 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2022.

Based on Birchview Capital's 13F filing for Q2 2022, filed 12 Aug 2022.